PVP Ventures Limited , a company listed on the Indian stock exchanges, has made significant changes to its leadership and audit structure. The company's Board of Directors has approved two major decisions:

New Statutory Auditor Appointment

The Board has appointed M/s. CNGSN Associates LLP as the new Statutory Auditors of the company. This appointment is intended to fill the casual vacancy created by the resignation of the previous auditors, M/s. PSDY Associates. The appointment is subject to shareholder approval.

Chief Financial Officer Resignation

Mr. K. Anand Kumar, the Chief Financial Officer (CFO) of PVP Ventures, has tendered his resignation. The Board has accepted his resignation, which will be effective from the close of business hours on December 8, 2025. Mr. Kumar is leaving to pursue other professional opportunities outside the organization.

Key Details of the Changes

The appointment of a new statutory auditor is a crucial decision for any publicly listed company, as it ensures the integrity and accuracy of financial reporting. The resignation of the CFO, a key management position, may lead to temporary changes in the financial leadership of the company.

PVP Ventures has duly informed the stock exchanges about these changes, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This transparency in reporting significant corporate events is crucial for maintaining investor trust and meeting regulatory requirements.

PVP Ventures Limited has successfully completed the first phase of its strategic acquisition of 7Med India Private Limited, a significant player in India's renal care sector. This move marks PVP Ventures' entry into the healthcare industry, diversifying its portfolio and potentially strengthening its market position.

Acquisition Details

PVP Ventures has acquired 14,939 equity shares of 7Med India, representing 33.24% of the company's total paid-up share capital. This initial stake is part of a larger acquisition plan that aims to secure a majority shareholding in 7Med India.

Financial Implications

The total transaction is structured as a combination of primary and secondary stake purchases, with an estimated outlay of approximately INR 127.00 crores for the majority shareholding of 50.62%.

About 7Med India

7Med India Private Limited is positioned among the top five organized players in India's renal care sector. The company offers a comprehensive range of dialysis services through its pan-India network. For the current financial year, 7Med India has reported an EBITDA of approximately INR 10.00 crore, indicating its strong performance in the healthcare market.

Strategic Rationale

This acquisition aligns with PVP Ventures' strategic initiative to diversify its business portfolio and establish a presence in the healthcare sector. By entering the renal care market through 7Med India, PVP Ventures is positioning itself in a growing and essential healthcare segment.

Regulatory Compliance

PVP Ventures has confirmed that this acquisition does not fall within the ambit of related party transactions. The company has also stated that no governmental or regulatory approvals were required for this acquisition.

As PVP Ventures continues to execute its acquisition strategy, market observers will be keen to see how this diversification into healthcare impacts the company's overall growth and market position in the coming years.